Adverum Biotechnologies Common Stock Net 2013-2025 | ADVM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adverum Biotechnologies common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adverum Biotechnologies common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$233.7B
Amgen (AMGN)	$153.4B
Gilead Sciences (GILD)	$148.9B
Vertex Pharmaceuticals (VRTX)	$99.4B
Bristol Myers Squibb (BMY)	$94.7B
CSL (CSLLY)	$83.8B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$59B
Alnylam Pharmaceuticals (ALNY)	$56.4B
Argenex SE (ARGX)	$39B
BioNTech SE (BNTX)	$26.7B
Insmed (INSM)	$25.8B
Royalty Pharma (RPRX)	$20.2B
Biogen (BIIB)	$18.9B
Incyte (INCY)	$15.9B
Illumina (ILMN)	$15B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$14B
Ascendis Pharma (ASND)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
QIAGEN (QGEN)	$10.9B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$10B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Exact Sciences (EXAS)	$7.9B
Halozyme Therapeutics (HALO)	$7.9B
Roivant Sciences (ROIV)	$7.9B